Novo Nordisk, the Danish weight-loss drug maker, posted third-quarter earnings ahead of expectations driven by impressive Wegovy pill sales, signaling a potential turnaround after a challenging year [1]. The company reported Q3 sales of 79.2 billion Danish kroner ($11.9 billion), representing 4% year-on-year growth and exceeding FactSet estimates of 73.6 billion kroner [1]. Adjusted operating profit (EBIT) reached 31.7 billion kroner, surpassing the expected 28.6 billion kroner [1].
Following the strong quarterly performance, Novo significantly improved its full-year guidance. The company now projects adjusted revenue and operating profit growth of between negative 2% and 2% at constant exchange rates, a substantial upgrade from its previous August guidance of negative 6% to flat for both metrics [1]. This revised outlook reflects renewed momentum for the company, which had fallen behind rival Eli Lilly during what the source describes as "a tumultuous year" [1]. The Wegovy pill's performance was particularly noteworthy, with sales "significantly exceeding analyst estimates in the third quarter," though specific sales figures for the product were not disclosed [1].
CONCLUSION
Novo Nordisk's better-than-expected Q3 results and raised full-year guidance demonstrate strong market demand for Wegovy and suggest the company is regaining competitive ground against Eli Lilly in the weight-loss drug market. The upgrade from negative 6% to a range of negative 2% to positive 2% for full-year growth represents a meaningful positive inflection point for the company's trajectory.